Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449751 | 0.95 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL450532 | 0.93 | ALDH1A1 (0.46) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL452237 | 0.92 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL451852 | 0.92 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL449456 | 0.92 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL448566 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL449305 | 0.91 | ALDH1A1 (0.44) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL449502 | 0.90 | CXCR3 (0.51) | CXCR3 | |
| SCHEMBL450155 | 0.89 | MAPT (0.43) | ALDH1A1KDM4EGAAHTTHPGD | |
| SCHEMBL454261 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2329822-A1 | Compositions and methods of treatment of cancer | Minerva Biotechnologies Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2116248-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | ALDH1A1 833/4885KDM4E 3917/4885GAA 2593/4885 |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885KDM4E 3717/4885GAA 1879/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | ALDH1A1 3161/4885KDM4E 3717/4885GAA 1879/4885 |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | ALDH1A1 674/4885KDM4E 4298/4885GAA 3187/4885 |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | ALDH1A1 833/4885KDM4E 3917/4885GAA 2593/4885 |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | ALDH1A1 833/4885KDM4E 3917/4885GAA 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.